MetrioPharm Investor Relations News QIII 2021
Greetings from CEO Thomas Christély
I would like to take the opportunity to introduce myself as the new CEO of MetrioPharm AG. In this role, I will focus primarily on business development and financing. Dr. Wolfgang Brysch will continue to lead the scientific strategy and medical development of MP1032 as Chief Scientific Officer.
Over the past few weeks, I have had several opportunities to meet with Dr. Brysch and other members of the team. Their passion and expertise were important reasons for me to take on this position. Just as important for this step was the great potential of the further development and commercialization of MP1032. This became clear during several discussions about the results achieved so far and the future strategy. I look forward to the tasks ahead which I will take on in cooperation with Dr. Brysch and the entire team.
Furthermore, I am keen to get in touch with you, dear shareholders, and to meet you personally. In the meantime, we will continue to keep you informed on a regular basis via our established channels about any changes, innovations and successes.
Thomas Christély is the Chief Executive Officer of MetrioPharm AG since October 1st 2021. He previously held positions as CEO, COO and CFO of private and public biotech and pharmaceutical companies for over 25 years, both in Europe and in the U.S. He has concluded more than 20 significant collaborations and licensing agreements with international pharmaceutical and biotech companies, including AstraZeneca, Pfizer and Novartis. Recently, in his position as managing director and CFO, he led the corporate development of the German pharmaceutical start-up MYR GmbH and its subsequent sale to Gilead Sciences Inc. for EUR 1.15 billion plus a potential milestone payment of further EUR 300 million. After his studies in Hamburg and Geneva, he received degrees in business and law and was admitted as attorney-at-law.
MetrioPharm in the Media
In August, MetrioPharm announced that Thomas Christély would join the company as its new CEO. This announcement was well received by several media outlets.
Among others, it was reported by the biotech platform Fierce Biotech the Swiss Handelszeitung, the Movers&Shakers section of the biotech platform BioSpace, as well as the magazine MedNous, which covers latest, medical developments in Europe in its print edition as well as on its website.
MetrioPharm on our Blog
To provide you with even more detailed information, we regularly publish background features on our MetrioPharm blog. In case you would like to receive blog updates, please message us at email@example.com.
Corporate Communications & Press Relations
T +49 (0) 30 33 84 395 53